Category Archives: R&D

NHL Treatment Market Boom Will Be Hindered in EU

The global non-hodgkin lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, according to GBI Research.
Also posted in Europe, Strategy | Tagged , , , , , , | Leave a comment

Gilead and Yale Extend Sequencing Initiative

After having already sequenced thousands of cancer genes in projects together, the Yale School of Medicine and Gilead announced they will continue their partnership to find therapeutic candidates for cancer for an additional three years. The original agreement was forged in 2011 and can be renewed for up to 10 years.
Also posted in Strategy, Technology | Tagged , | Leave a comment

The Baltic States: A Location for Your Next Clinical Trial

The Baltic States with its appropriate population size, sufficient infrastructure, and experienced and motivated investigators, make it an attractive choice for a clinical trial. In this article, Doatas Grina, Indre Tutlyte and Auudius Sveikata, PhD, that ran in the February 2013 issue of Applied Clinical Trials, presents a persuasive case for the area’s present desirability as well as […]
Also posted in Europe, Global | Tagged , | Leave a comment

Cancer Medicines: Setbacks and Stepping Stones

A report released on this week by the Pharmaceutical Research and Manufacturers of America (PhRMA), “Researching Cancer Medicines: Setbacks and Stepping Stones,” highlights the number of investigational cancer medicines that did not succeed in clinical trials and how these so-called “failures” are a crucial part of the drug development process.
Also posted in healthcare | Tagged , , , , | 1 Comment

Hemispherx’s Five Ebola Research Collaborations

Hemispherx Biopharma (Philadelphia, PA) has announced a  set of research collaborations designed to develop “therapeutic cocktails against Ebola which may potentially overcome the emergence of drug resistance due to Ebola virus mutation”.
Also posted in Biotech, Global, healthcare | Tagged , , | Leave a comment
  • Categories

  • Meta